Yahoo Finance

Dianthus to take gMG mAb to Phase III after mid-stage win

Dianthus Therapeutics’ claseprubart has met its primary and secondary endpoints during a Phase II trial in generalised myasthenia gravis (gMG). During the MaGic study (NCT06282159), the active ...